Skip to main content
. 2022 Dec 1;8:e2200205. doi: 10.1200/GO.22.00205

FIG 3.

FIG 3

(A) The global health status/QoL and (B) physical function score based on the EORTC-QLC C30 and (C) HCC symptoms score index using the EORTC-QLQ-HCC18 at baseline, 3, 6, 9, and 12 months of atezolizumab and bevacizumab treatment. EORTC-QLC C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; HCC, hepatocellular carcinoma; QoL, quality of life.